EGFR mutation and ALK translocation testing is done in private laboratories, and usually, pharmaceutical companies sponsor the test.33 Across LATAM countries, it is estimated that < 30% of patients with lung adenocarcinomas are tested for EGFR and only approximately 10% are tested for ALK fusion. The gene discussed is ALK; the disease is lung adenocarcinoma.